ライフサイエンスコーパス: cancer patient

1 l properties in both healthy individuals and cancer patients.

2 elate with metastatic status in human breast cancer patients.

3 identified 1,265,684 hospitalized colorectal cancer patients.

4 correlates with poor prognosis among breast cancer patients.

5 engineered mouse model and human pancreatic cancer patients.

6 elumetinib response in tumours from 23 colon cancer patients.

7 for known prognostic factors in young breast cancer patients.

8 s and for skeletal complications in prostate cancer patients.

9 es, similar to early detection procedures in cancer patients.

10 ive biomarker for clinical outcome of breast cancer patients.

11 h cancer progression and clinical outcome in cancer patients.

12 bitor in the treatment of MFN2 downregulated cancer patients.

13 as a new radioligand for uPAR PET imaging in cancer patients.

14 AZD9291 and selumetinib to EGFR-mutant lung cancer patients.

15 d was associated with poor survival of colon cancer patients.

16 gets for reducing tumor recurrence in breast cancer patients.

17 tissue collected from in-house Chinese liver cancer patients.

18 h different long-term outcomes in pancreatic cancer patients.

19 orrelate with reduced survival of colorectal cancer patients.

20 (CTCs) selected from the peripheral blood of cancer patients.

21 nalysis on drug-stratified subpopulations of cancer patients.

22 e for the CD28/B7 pathway in PD-1 therapy of cancer patients.

23 rrelate with poor clinical outcome in breast cancer patients.

24 evasion, and ultimately to poor prognosis of cancer patients.

25 a expression in tissue samples of pancreatic cancer patients.

26 on chemosensitivity and prognosis of ovarian cancer patients.

27 ective individualized platforms for treating cancer patients.

28 e lesions were detected in 12 of 12 prostate cancer patients.

29 predicts a poor clinical outcome for breast cancer patients.

30 d for many years for the treatment of breast cancer patients.

31 ed a remarkable clinical response in certain cancer patients.

32 rs (PARPi) benefit only a fraction of breast cancer patients.

33 niche formation and poor prognosis in breast cancer patients.

34 immunotherapies are promising treatments for cancer patients.

35 th (68)Ga-NeoBOMB1 were acquired in prostate cancer patients.

36 (81%) on 5,338 TMA images from 1,853 breast cancer patients.

37 and potent alternative therapy for prostate cancer patients.

38 d ascites cells isolated from serous ovarian cancer patients.

39 dent prognostic factor for metastatic breast cancer patients.

40 rlotinib treatment in 50 non-small cell lung cancer patients.

41 be applicable to a much wider population of cancer patients.

42 CNTD2 and decreased overall survival in lung cancer patients.

43 iversity of Pittsburgh Medical Center breast cancer patients.

44 simetry of (18)F-FAZA in non-small cell lung cancer patients.

45 validation cohort consisting of 63 laryngeal cancer patients.

46 d primary and metastatic tissues from breast cancer patients.

47 bent assay (ELISA) in saliva samples of oral cancer patients.

48 esting of HER2 in clinical samples of breast cancer patients.

49 ciated with a shorter survival in metastatic cancer patients.

50 dance was increased in the plasma of ovarian cancer patients.

51 r drug resistance limit survival outcomes in cancer patients.

52 ognoses and decreased survival in pancreatic cancer patients.

53 ch may serve as a prognostic marker for lung cancer patients.

54 ssed gene signature that can stratify breast cancer patients.

55 ts in a significant number of advanced-stage cancer patients.

56 ncers and signifies poor prognosis of breast cancer patients.

57 n on urinary N-glycans derived from prostate cancer patients.

58 e precision oncology and value-based care to cancer patients.

59 level and guide the precision treatment for cancer patients.

60 of circulating free tumour DNA obtained from cancer patients.

61 sociated with better prognosis in all breast cancer patients.

62 27 Ab, varlilumab (clone 1F5), is ongoing in cancer patients.

63 on of circulating tumor DNA in the plasma of cancer patients.

64 ations remained as high as 92% in 7/10 renal cancer patients.

65 w biomarker for the prognosis of gallbladder cancer patients.

66 hibited efficacy in only a small fraction of cancer patients.

67 correlates well with poor survival of breast cancer patients.

68 ease in overall survival in colon and breast cancer patients.

69 of multiparametric imaging in head and neck cancer patients.

70 n is associated with better survival of lung cancer patients.

71 n BRCA1 or BRCA2 define a subset of prostate cancer patients.

72 treatment response assessment in pancreatic cancer patients.

73 diol ((18)F-FES) in ER-positive (ER+) breast cancer patients.

74 his has not been well-characterized in human cancer patients.

75 etastasis is a major health threat to breast cancer patients.

76 umor samples from 30 muscle-invasive bladder cancer patients.

77 s for appropriate diagnosis and treatment to cancer patients.

78 laborate for widespread application to treat cancer patients.

79 ive nodal status, and poor survival of colon cancer patients.

80 otein level but not mRNA level in colorectal cancer patients.

81 of the most common causes of mortality among cancer patients.

82 aximize the benefits of radiation for breast cancer patients.

83 glutamate metabolism metal transport in oral cancer patients.

84 s found in the circulatory system of certain cancer patients.

85 rc kinases, paxillin, and survival of breast cancer patients.

86 can in erlotinib-treated non-small cell lung cancer patients.

87 with poor gemcitabine response in pancreatic cancer patients.

88 cancer cells from neoadjuvant-treated breast cancer patients.

89 stic marker and therapeutic target in breast cancer patients.

90 formation from electronic medical records of cancer patients.

91 te the feasibility of our approach in breast cancer patients.

92 lore the critical role of CAR in survival of cancer patients.

93 e yielded little clinical benefit for breast cancer patients.

94 Metastasis is the leading cause of death for cancer patients.

95 obtained from castration-resistant prostate cancer patients.

96 entration predicts poor prognosis of non-CNS cancer patients.

97 es for guiding treatment decisions in breast cancer patients.

98 en is still an unmet medical need for breast cancer patients.

99 dependent data sets with totally 1079 breast cancer patients.

100 clinical responses in a sizable minority of cancer patients.

101 is a target for endocrine therapy in breast cancer patients.

102 and cancer type-specific pathways of VTE in cancer patients.

103 ly correlates with disease prognosis in lung cancer patients.

104 of 6 studies conducted in the US in 317,243 cancer patients (98% of all patients) the CIR of active

105 -centric patient presentation score to 9,176 cancer patients across 1,018 recurrent oncogenic mutatio

106 er, non-small cell lung cancer, and non-lung cancer patients all dropped below 20%.

107 Management of pericardial disease in cancer patients also posed clinical challenges.

108 miRNA was isolated from 50 early-stage colon cancer patients and 50 matched healthy volunteers.

109 of 81.3% at a specificity of 90% (16 bladder cancer patients and 8 healthy controls).

110 s) are correlated with positive prognoses in cancer patients and are used to determine the efficacy o

111 lation (CIR) of new cases of TB occurring in cancer patients and comparative incidence rate ratios (I

112 ed eluates by SRM (SAFE-SRM), to plasma from cancer patients and discovered two peptides encoded by t

113 demonstrated functional activity in 100% of cancer patients and healthy volunteers; which was signif

114 ripheral blood T cells is impaired in breast cancer patients and is associated with blunted Th17 diff

115 zed gene expression profiles of human breast cancer patients and patient-derived xenograft (PDX) samp

116 rrelates with a high IGFBP3 status in breast cancer patients and predicts a poor clinical outcome for

117 tributor to morbidity and mortality for many cancer patients and remains a major obstacle for effecti

118 lts validate Plk4 as a therapeutic target in cancer patients and reveal a new role for Plk4 in regula

119 autophagy-inducing bioactivity in serum from cancer patients and that this is clearly associated with

120 nregulation of gp130 and IL6Ralpha in breast cancer patients and was independent of plasma IL6 levels

121 ng EV from the plasma of metastatic prostate cancer patients and was LO specific.

122 orphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype stat

123 of peptide sequences identified by comparing cancer patients' and healthy donors' global peptide prof

124 ively enriched in the tumor stroma of breast cancer patients, and depletion of these factors from nor

125 ay provide additional benefit for esophageal cancer patients, and merits further investigation.

126 4 is currently undergoing clinical trials in cancer patients, and our experiments highlight concerns

127 e prognostic biomarker in ER positive breast cancer patients, and predictive of preclinical sensitivi

128 cancer immunotherapy stem from the fact that cancer patients are either refractory to immune response

129 f better postoperative recovery programs for cancer patients are needed to enhance survival after sur

130 echanisms driving cell migration in prostate cancer patients are not fully understood.

131 of this drug in brain tumour lesions of lung cancer patients, as penetration of the blood-brain barri

132 potentially exploitable for the selection of cancer patients at the highest chance of benefit from co

133 hether survival differed for invasive breast cancer patients based on hormone receptor (HR) status an

134 ured with the use of indirect calorimetry in cancer patients before the initiation of anticancer ther

135 In tumor tissue from breast cancer patients, beta3 was significantly elevated on bon

136 reporting 593 TB cases occurring in 324,041 cancer patients between 1950 and 2011 were identified.

137 -regulated in lung adenocarcinomas from lung cancer patients, both at the mRNA and protein levels, an

138 s the potential to improve the management of cancer patients, but further research is required before

139 Neutrophils could increase VTE in cancer patients by releasing neutrophil extracellular tr

140 radiosensitivity in 134 non-small-cell lung cancer patients, by using K-Means clustering to group pa

141 rofiling is increasingly being used to guide cancer patient care, especially in advanced and incurabl

142 targeted PARP-inhibitor therapies in ovarian cancer patients carrying deleterious missense RAD51D var

143 muscle wasting in mice.Cachexia affects many cancer patients causing weight loss and increasing morta

144 ssociated with poorer survival in the breast cancer patient cohort (n = 1441).

145 vivo information could impact management of cancer patients considerably.

146 personalized treatment strategies for breast cancer patients could be improved by considering both ge

147 he leading cause of death in advanced breast cancer patients, depend on tumor cell interactions with

148 profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models.

149 experiments performed in 4 different gastric cancer patient-derived xenograft models showed low uptak

150 y identified 4932 eligible metastatic breast cancer patients diagnosed between 2010-2013, including 8

151 other breast tumor subtypes or older breast cancer patients did not seem to benefit effects of RT.

152 d rapamycin (Rapa), commonly administered to cancer patients, elevate glucose and sensitize cardiomyo

153 ificantly increase response rates for breast cancer patients, especially those with HER2 and ER negat

154 zed data from 249,010 hospital-based English Cancer Patient Experience Survey responders with sexual

155 strains representing common alleles found in cancer patients failed to complement in these assays.

156 site for identifying methods to treat breast cancer patients featuring such mutations.

157 g modality in biochemical recurrent prostate cancer patients for N staging.

158 mbined with radiation in Non-Small Cell Lung Cancer patients for use in clinical trial design.

159 = 211,718) and cancer registration data for cancer patients for years 1987 to 2012.

160 chemo-radiation treatments for head-and-neck cancer patients from different risk groups.

161 ograft model and correlation studies in lung cancer patients further validated the clinical relevance

162 loop of pri-mir-30c-1 in breast and gastric cancer patients had been previously described to result

163 om the pre- and post-treatment CT of bladder cancer patients has the potential to assist in assessmen

164 These differences may explain why pediatric cancer patients have a higher risk of developing treatme

165 Cancer patients have an increased risk of venous thrombo

166 nchymal cell lines from ascites of a bladder cancer patient (i.e. cells already migrated outside prim

167 ng of autoantibodies (AutoAbs) from prostate cancer patients identified the 78-kDa glucose-regulated

168 er (BC) is the main cause of death of female cancer patients in China.

169 tide vaccines administered to HER2(+) breast cancer patients in the adjuvant setting suggest synergy

170 ocal recurrence and survival in young breast cancer patients in the Prospective study of Outcomes in

171 always translated into improved survival of cancer patients, in part due to the suboptimal propertie

172 ion is correlated with low survival rates in cancer patients, including nasopharyngeal carcinoma (NPC

173 rculating tumor cells (CTCs) in the blood of cancer patients is a challenging task.

174 systemic therapy in the treatment of breast cancer patients is increasing beyond the scope of locall

175 ogical responses induced by PD-1 blockade in cancer patients is lacking.

176 Treatment of stage IV metastatic breast cancer patients is limited to palliative options and rep

177 Early palliative care integration for cancer patients is now touted as the optimal care model,

178 ow IL6 modulates the host immune response in cancer patients is unclear.

179 urate drug response data in large cohorts of cancer patients is very challenging; thus, most cancer p

180 ury and its long-term processes is needed as cancer patients live longer.

181 and vomiting associated with chemotherapy in cancer patients, lymphocytes from those patients were us

182 tanding of the pathways that increase VTE in cancer patients may lead to the development of new thera

183 In 147 prostate cancer patients (mean age, 68 y; range, 44-87 y) with pr

184 n the ICU can be lifesaving in very selected cancer patients, most especially with small cell lung ca

185 ry EVs was significantly elevated in bladder cancer patients (n = 16) compared to healthy controls (n

186 gs were validated using data from colorectal cancer patients (n = 261).

187 Here, we show in mice and cancer patients (n = 70) that lung adenocarcinomas incre

188 Because cancer patients often have coexisting heart diseases, ex

189 ur in approximately 70% of metastatic breast cancer patients, often leading to skeletal injuries.

190 (<40 y group) with that in a group of breast cancer patients older than 40 y (>/=40 y group).

191 rrelates with better prognosis in pancreatic cancer patients on fluoropyrimidine analogs.

192 s were developed for 30 consecutive cervical cancer patients on the basis of computed tomography: IPS

193 those associating with exosomes from breast cancer patients or controls.

194 teolytic peptides derived from the plasma of cancer patients or healthy individuals.

195 cal management and may ameliorate colorectal cancer patient outcomes.

196 se expression correlates with the colorectal cancer patients' overall survival.

197 Forty-five rectal cancer patients, partial responders (PR = 18), nonrespon

198 ng to diverse phenotypic consequences across cancer patient populations.

199 ed that high serum resistin levels in breast cancer patients positively correlated with tumor stage,

200 ripheral blood mononuclear cells (PBMC) from cancer patients produced high NO levels.

201 ectin-3, which is increased up to 30-fold in cancer patients, promotes blood-borne metastasis in an a

202 l impedance analysis in 128 gastrointestinal cancer patients provided with or without FO-enriched nut

203 supports Honokiol as a promising therapy for cancer patients receiving Dox treatment.

204 rocedure performed, demonstrates that breast cancer patients receiving neoadjuvant chemotherapy have

205 The high mortality rates of cancer patients receiving standard treatments emphasize

206 were examined retrospectively for 65 thyroid cancer patients, referred to determine (131)I uptake and

207 l S100, especially the mRNA level, in breast cancer patients remain elusive.

208 The true impact for cancer patients remains unclear.

209 Further capturing of CTCs from metastatic cancers patients revealed a positive capture rate of 83.

210 DDX3 expression was present in 35% of breast cancer patient samples and correlated with markers of ag

211 Consistently, breast cancer patient samples portrayed a strong and significan

212 p encoding the clock gene PER1 in colorectal cancer patient samples.

213 ssion levels in a collection of 119 prostate cancer patient samples.

214 Notably, up to 70% of cancer patients showed a heterozygous deletion or missen

215 uman oestrogen receptor (ER)-negative breast cancer patients showed a strong correlation between phos

216 alized care and survival outcomes of ovarian cancer patients.Significance: Epigenomic targeting may i

217 relapse-free and overall survival in breast cancer patients, suggesting that modulation of ER-Golgi

218 cer cell lines and in tumors from colorectal cancer patients that progressed on cetuximab.

219 urrent mechanism of resistance in colorectal cancer patients that was not seen in similarly resistant

220 To accommodate future needs of breast cancer patients, the companion diagnostic model will con

221 lthough many of these drugs are effective in cancer patients, the response is often not durable becau

222 Among breast cancer patients, those diagnosed with the triple-negativ

223 er repertoire of new T-cell specificities in cancer patients, tipping the intra-tumoural balance in f

224 se of the Institute of Medicine report: From cancer patient to cancer survivor: lost in transition, i

225 f the 2005 Institute of Medicine Report From Cancer Patient to Cancer Survivor: Lost in Transition.

226 function of the oral microbiomes of 121 oral cancer patients to 242 age- and gender-matched controls

227 weeks to months to evaluate the response of cancer patients to a drug.

228 logy that allows disease trajectories of the cancer patients to be estimated from free text in electr

229 pathological response and outcome of breast cancer patients to chemotherapy early following treatmen

230 d experimental data sets from two colorectal cancer patients to trace evolutionary lineages in primar

231 tential biomarker for the response of breast cancer patients to Vinca alkaloid drug treatment.

232 ellSearch system via parallel analysis of 30 cancer patients, to find no significant difference betwe

233 In ovarian cancer patients treated with bevacizumab, serum MSMP con

234 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in fi

235 termined the HLA-I genotype of 1535 advanced cancer patients treated with immune checkpoint blockade

236 Elderly cancer patients treated with ionizing radiation (IR) or

237 In lung cancer patients treated with mTOR inhibitor RAD001, we o

238 ACOSOG Z1071 enrolled cT0-4N1-2 breast cancer patients treated with neoadjuvant chemotherapy fr

239 In node-positive breast cancer patients treated with neoadjuvant chemotherapy, B

240 onsequences in human disease: in a cohort of cancer patients treated with radiation, Wwox deficiency

241 articipants included 5569 early-stage breast cancer patients, treated with breast-conserving surgery

242 i-scale modeling is then performed on a lung cancer patient under conventional fractionated irradiati

243 In breast cancer patients undergoing doxorubicin therapy, early al

244 One hundred twenty head and neck cancer patients underwent 0- to 30-min (18)F-FMISO dPET

245 hree hundred forty-eight non-small cell lung cancer patients underwent diagnostic (18)F-FDG PET scans

246 Among tumors from 188 oral cancer patients, upregulated ROS1 expression strongly co

247 dology to profile N-glycans from 58 prostate cancer patient urine samples, revealing increased sialya

248 In a cohort of 1,596 breast cancer patients, we analyzed the associations of 33 labo

249 ver metastasis is the main cause of death in cancer patients, we attempted to identify the driver gen

250 ed samples from 11 high-grade serous ovarian cancer patients, we detected 2-20-fold more sN4 in ascit

251 t (DWI/ADC) images of 86 lymph nodes from 31 cancer patients were analyzed.

252 e alterations in the oral microbiome of oral cancer patients were significant, they were of substanti

253 ely correlated in tissue samples from breast cancer patients, where high expression of both BCAR4 and

254 STYX and FBXW7 are anti-correlated in breast cancer patients, which affects disease prognosis.

255 levels negatively correlate with survival of cancer patients, which is generally attributed to the di

256 tory tests is powerful in identifying breast cancer patients who are at high risk of recurrence.

257 e-treatment T2-weighted MRI between prostate cancer patients who do (BCR (+)) and do not (BCR (-)) ha

258 no basis to prescribe statins to colorectal cancer patients who do not have cardiovascular indicatio

259 ial clinical response in non-small cell lung cancer patients who harbor activating mutations in EGFR.

260 Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or

261 Importantly, breast cancer patients who responded to letrozole expressed sig

262 senting novel therapeutic targets for breast cancer patients who smoke.

263 orectal excision for locally advanced rectal cancer, patients who experience local or systemic relaps

264 Importantly, breast cancer patients whose tumors express both low stromal JA

265 R expression has been visualized in prostate cancer patients with (18)F-fluorodihydrotestosterone ((1

266 n surgically treated, node-positive prostate cancer patients with (ENE+) vs. without (ENE-) ENE.

267 ment in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received

268 btained from EGFR-mutant non-small-cell lung cancer patients with acquired EGFR tyrosine kinase inhib

269 Curative therapy for cancer patients with advanced-stage disease remains elus

270 tor splice variant 7 in a cohort of prostate cancer patients with an overall concordance of 92% betwe

271 To describe trends in outcomes of cancer patients with an unplanned admission to the ICU b

272 agement changes in more than 50% of prostate cancer patients with BCR (54/101; 53%).

273 fects the implemented management of prostate cancer patients with biochemical recurrence (BCR).

274 mor cells in the bone marrow from colorectal cancer patients with bone metastases.

275 Characterization of CTCs derived from breast cancer patients with brain metastasis (BCBM) may allow f

276 val and shorter disease-specific survival of cancer patients with different molecular subtypes of bre

277 was also found in primary tumors from colon cancer patients with distant metastases.

278 uld be considered when systemically treating cancer patients with heparanase inhibitors, since the po

279 get to enhance conventional chemotherapy for cancer patients with high levels of TCTP expression.

280 nd LumB breast cancer subtypes of 512 breast cancer patients with invasive ductal carcinoma (IDC).

281 Here, we report that breast cancer patients with low MFN2 expression are associated

282 with human colorectal tumors, and colorectal cancer patients with low protein expression of SIRT1 hav

283 ne expression profile of luminal-type breast cancer patients with low RB expression revealed high enr

284 Human colon cancer patients with more advanced disease show higher l

285 me cancers, and a greater proportion of AIAN cancer patients with multiple comorbid conditions.

286 n following treatment of ALK or ROS1(+) lung cancer patients with oncogene-targeted therapy ultimatel

287 Finally, not only do oral cancer patients with p53 mutations exhibit higher levels

288 s a promising therapeutic target for ovarian cancer patients with recurrent UBB silencing.

289 ity when compared with a liberal strategy in cancer patients with septic shock.

290 g an improved strategy for preventing BTP in cancer patients with skeletal metastases.

291 n identifies mutant KRAS lung and pancreatic cancer patients with the worst survival outcome.

292 AMF could be detected in serum or urine of cancer patients with worse prognosis.

293 We identified CH in 25% of cancer patients, with 4.5% harboring presumptive leukemi

294 hways, are now available for clinical use in cancer patients, with other interesting checkpoint inhib

295 eatment upon survival for cT3N0M0 esophageal cancer patients, with subgroup analyses by histological

296 y using Hsp90 to improve outcomes for breast cancer patients without affecting traditional care pathw

297 ression using a matched comparison cohort of cancer patients without pericarditis.

298 ofusion of sequence information derived from cancer patients worldwide stymies basic research and cli

299 ty-related cytokine-is upregulated in breast cancer patients, yet its impact on breast cancer behavio

300 nitial (18)F-FDG PET/CT in a group of breast cancer patients younger than 40 y (<40 y group) with tha